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ABSTRACT
Calciphylaxis, or calcific uraemic arteriolopathy (CUA), represents a life-threatening disease. Dialysis patients and those
receiving warfarin are seen as populations at higher risk for CUA. Treatments for CUA are still uncertain despite the
poor survival of the disease. Administration of intravenous sodium thiosulphate (STS) has been purposed to treat CUA
in dialysis patients. Due to the poor tolerability of STS, characterized by nausea, hypocalcaemia, metabolic acidosis and
QT-interval prolongation, its intralesional administration has been reported. We herein present the improvement of
wounds in a haemodialysis patient affected by CUA, treated by multipronged intervention including both intravenous and
intralesional STS.
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INTRODUCTION
Calciphylaxis, or calcific uraemic arteriolopathy (CUA), repre-
sents a life-threatening disease, characterized by microvascular
occlusion in subcutaneous adipose tissue and dermis [1].
Clinical presentation consists of painful skin lesions, any poten-
tially interesting district of cutis and internal organs. Lesions
may evolve rapidly, starting with nodules, purpura and livedo,
thereafter leading to jagged ulcers with black scars. To date,
chronic dialysis patients and those receiving warfarin are those
at greatest risk of CUA. Chronic kidney disease–mineral bone
disorder syndrome, with deranged mineral metabolism and
extraskeletal calcification, accounts for the major risk factor
for CUA in end-stage renal disease (ESRD). Hyper–hypoparathy-
roidism together with calcium-based phosphate (P) binders, alu-
minium and vitamin D administration are additive triggers of
CUA in dialysis. Warfarin may induce calciphylaxis, downregu-
lating the matrix Gla protein, a constitutive inhibitor of vascular
calcification, through vitamin K inhibition.
Despite the poor survival observed among CUA patients,
knowledge of the mechanisms of and treatments for the disease
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are scanty. Multipronged intervention is suggested against CUA,
based on a physiology-driven approach and clinical reports. The
interdisciplinary management includes histological diagnosis,
wound care, analgesia, nutritional support, correction of min-
eral parameters, intensive haemodialysis (HD), sodium thiosul-
phate (STS), calcimimetic bisphosphonate, hyperbaric oxygen
therapy and withdrawal of iatrogenic factors such as warfarin,
calcium-based binders and vitamin D [1].
Off-label intravenous (i.v.) infusion of STS has been reported
to improve skin lesions in HD patients affected by CUA, at the
dose of 25 g thrice weekly (TIW) after dialysis for 3 months. Dose
reduction to 12.5 g TIW for body weight <60 kg has been sug-
gested [2, 3]. However, doses and frequency of STS may be lim-
ited by side effects such as anion gap metabolic acidosis,
hypocalcaemia, QT-interval prolongation and nausea. For these
reasons, intralesional STS administration has been reported in
isolated cases of CUA [4, 5].
We report the case of an HD patient affected by CUA, im-
proved by multifactorial therapy including both i.v. and intrale-
sional STS infusion.
CASE REPORT
A 70-year-old African male was admitted to the renal unit due
to painful ulcers at the middle third of right leg and left ankle.
Clinical history was suggestive for ESRD secondary to vascular
nephropathy, receiving TIW HD by native arterovenous fistula
for 11 years, thrombosis of superior vena cava, secondary hyper-
parathyroidism with hyperphosphataemia, arterial hyperten-
sion, turbercular infection and gastric bleeding in the past. At
admission, his medical therapies were acenocoumarol, i.v. pari-
calcitol, calcium carbonate, sevelamer carbonate, acetylsalicylic
acid, nifedipine, bisoprolol, sodium polystyrene sulphonate,
omeprazol and epoetin beta. CUA was suspected and shortly af-
ter was confirmed by histological examination at the right leg
ulcer (Figure 1). The following multipronged intervention was
established (Figure 2): (i) withdrawal of oral anticoagulant (com-
plete resolution of central venous thrombosis was ruled out at
computed tomography scan examination), calcium carbonate
and vitamin D; (ii) increased dialysis dose up to five to six hae-
modiafiltration sessions per week with low calcium dialysate
(1.25 mmol/L); (iii) hyperbaric therapy (10 sessions); (iv) i.v. STS
at the dose of 12.5 g post-dialysis TIW according to body weight
(nine doses) then tapered to 9 g TIW (due to persisting nausea
and mild high anion gap metabolic acidosis, requiring daily ad-
ministration of oral sodium bicarbonate) and shortly after re-
duced to 9 g weekly in a single dose with remission of nausea
(still ongoing at the time of submission); (v) intralesional STS
[prepared vials of STS (1 g/10 mL), of which 200 mg (2 mL) were
aspirated purely (without diluent) into a 2.5 mL syringe, then
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FIGURE 1: Iconographic report. (A) Histology (haematoxylin–eosin and Von Kossa staining) of cutaneous biopsy performed at the border of right leg. Asterisks indicate
basophil intraluminal calcifications; solid arrows: fibrointimal hyperplasia; dashed arrow: intraluminal calcifications typical of calciphylaxis. (B) Pictures of the right
leg ulcer. Arrow: site of biopsy. (C) Pictures of the left heel ulcer. (D) Intralesional administration of STS.
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the 200 mg were inoculated sterilely as small boluses in a cir-
cumferential direction along the edges of the lesion at the right
leg on Day 14 and at the left heel on Day 27]; (vi) surgical debrid-
ments; (vii) vacuum-assisted closure therapy; (viii) successful
percutaneous transluminal angioplasty (PTA) of the anterior
and posterior right tibial arteries and partially successful PTA of
the left interosseous and anterior tibial arteries; (ix) empiric an-
tibiotic prophylaxis (vancomicine plus levofloxacine); (x) nutri-
tional support; and (xi) low-dose buprenorphine transdermal
patch. The association with oral cinacalcet was attempted, but
immediately interrupted due to gastric intolerance.
Intralesional infusions of STS were well tolerated with the ex-
ception of pain during infusion. No particular worsening of met-
abolic acidosis or hypocalcaemia was detected across the
inoculation of STS. During 36 days of in-hospital observation,
pain was quickly controlled and leg ulcers engaged a favourable
healing process without infective complications or new-onset
ulcers. Metabolic acidosis, calcaemia and QT interval were well
controlled. Leg ulcers underwent rapid improvement during
10 days after discharge, with ambulatory wound care provided
at a vulnological clinic (Figure 1). Wound care thereafter pro-
ceeded at an ambulatory setting without the need of further in-
hospital admissions. At Day 108, restitutio ad integrum was ob-
served at the right leg and considerable healing was even seen
at the left heel.
DISCUSSION
This is the second case of CUA treated with both i.v. and local
STS administration to date [4]. Intralesional STS may represent
a tolerable and adjuvant step to improve CUA healing, espe-
cially for patients with poor tolerance to i.v. STS at maximum
doses. However, as multipronged therapy looks crucial against
CUA, mutifactorial intervention weakens our understanding of
the effect of single factors, such as local STS. In particular, it
remains impossible to discriminate whether i.v. and intrale-
sional STS had the strongest effect in improving the healing
process, compared with the standard multipronged interven-
tion. Furthermore, a longer follow-up is required to estimate the
final benefits of this approach against life-threatening CUA. The
effect of intralesional STS on acid–base balance requires further
investigation.
NOTE
Basal levels of 25-hydroxyvitamin D were 7.16 ng/mL, which
were not thereafter replenished in the presence of CUA. Only
mild hypocalcaemia was observed, allowing adoption of 1.25 Ca
dialysate, without the need of Ca infusion. Trends of inflamma-
tory markers looked to be associated, at least partially, with sur-
gical and endovascular interventions, while their basal values
FIGURE 2: Medical intervention and biochemical parameters. An. gap: anion gap; Caþþ: ionized calcium; CRP: C-reactive protein; Debrid. Med.: debridment, medication;
HCO3: bicarbonate standard; iPTH: intact parathyroid hormone; Lactic Ac: lactic acid; Mg: serum magnesium; OT: oxygen therapy; P: serum phosphate; PCT: procalci-
tonin; Sevelamer C: sevelamer carbonate; VAC: vacuum-assisted closure therapy; ALP: alkaline phosphatase.
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looked more compatible with chronic inflammation in the pres-
ence of CUA, rather than to overcome infections. Trend in para-
thyroid hormone values was attributed to the initial suspension
of vitamin D activator and calcium carbonate, followed by the
desired rapid reduction of serum P levels. At our institution, the
target of circulating P levels was arbitrarily set to 2.5–3.0 mg/dL
in the presence of CUA. Nutritional counselling was adopted for
ensuring an adequate protein and caloric intake and, especially,
for increasing dietary P intake whenever circulating P went
<2.5 mg/dL. Calcium–aluminium-free P binder was tailored ac-
cordingly. Of note, only mild reduction of circulating albumin
was observed during in-hospital stays.
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